Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases: pooled data from four trials
C. Valenzuela (Madrid, Spain), S. Assassi (Houston, Texas, United States of America), F. Bonella (Essen, Germany), T. Maher (Los Angeles, California, United States of America), L. Loaiza (Ingelheim am Rhein, Germany), I. Tschoepe (Bietigheim-Bissingen, Germany), L. Orsatti (Ingelheim am Rhein, Germany), M. Kolb (Hamilton, Ontario, Canada)
Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Valenzuela (Madrid, Spain), S. Assassi (Houston, Texas, United States of America), F. Bonella (Essen, Germany), T. Maher (Los Angeles, California, United States of America), L. Loaiza (Ingelheim am Rhein, Germany), I. Tschoepe (Bietigheim-Bissingen, Germany), L. Orsatti (Ingelheim am Rhein, Germany), M. Kolb (Hamilton, Ontario, Canada). Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases: pooled data from four trials. 2539
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016
Yoga in patients with fibrosing interstitial lung diseases – a feasibility trial Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020
Efficacy of rituximab in patients with connective tissue disease associated interstitial lung disease: Preliminary results in safety and clinical response Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012
Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015
Nintedanib in patients with chronic fibrosing interstitial lung diseases with progressive phenotype: the INBUILD trial Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016
Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021
Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021
A prosprective study on the safety, tolerability and efficacy of pirfinidone in the treatment of idiopathic pulmonary fibrosis and fibrotic NSIP Source: Annual Congress 2012 - Cystic lung diseases: lung granulomatosis Year: 2012
All-case post-marketing surveillance (PMS) of pirfenidone in Japan: Clinical characteristics, efficacy and safety profile in >1300 patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013
Clinical trials in interstitial lung disease Source: Eur Respir Mon; 2009: 46: 67–84 Year: 2009
Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice Source: ERJ Open Res, 4 (4) 00049-2018; 10.1183/23120541.00049-2018 Year: 2018
Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021
Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA Source: Eur Respir J, 52 (1) 1702106; 10.1183/13993003.02106-2017 Year: 2018
The long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): Interim data from the RECAP extension study Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2011
Outcomes of patients with progressive fibrosing interstitial lung disease (PF-ILD) – data from a prospective ILD registry Source: Virtual Congress 2021 – The future of idiopathic pulmonary fibrosis Year: 2021
Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020
Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results Source: International Congress 2014 – Clinical trials in IPF Year: 2014
Safety and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) receiving commonly used concomitant medications Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012
Efficacy and safety of etanercept in patients with idiopathic pulmonary fibrosis (IPF) Source: Eur Respir J 2006; 28: Suppl. 50, 767s Year: 2006